(King of Prussia, PA; May 14, 2015) - Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, will open a new, state-of-the-art clinical supplies facility in Frankfurt, Germany, in June.
The current good manufacturing practice (cGMP)-compliant facility will triple Theorem’s current clinical supplies capacity, with space for 2,700 square meters of ambient (15 to 25°C) and refrigerated (2 to 8°C) space. The opening also positions Theorem’s clinical supplies hub near the Frankfurt Airport, a major transportation hub.
“We’re excited to have the additional manufacturing and warehousing space and, more importantly, an infrastructure to deliver the flexibility our clients rely on,” said John Potthoff, Theorem president and CEO. “The new facility will enhance speed and scalability while preserving the versatility of our supply solutions.”
Theorem packages, labels, stores, distributes and reclaims pre-randomized study drugs and medical devices for studies worldwide. Theorem also provides qualified person services, as well as a range of temperature-controlled transport and logistics solutions, to facilitate the supply of global clinical trials. The launch of the new facility will strengthen current practices - such as its 24/7/365 storage, continuous monitoring and backup - and provides space for future service expansion.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.